Project Grant DP2CA311214
- The project "ENGINEERING NATURAL KILLER CELLS TO TARGET ACUTE MYELOID LEUKEMIA WITH HLA-DR LOSS" is being funded by a $429,000 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded to Western University of Health Sciences in California. The goal of this 3-year research project is to develop a novel chimeric antigen receptor (CAR) natural killer (NK) cell therapy that can specifically target acute myeloid leukemia (AML) with loss of the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $192,564.00 to The Ohio State University to develop a natural killer (NK) cell-based immunotherapy for the treatment of pediatric solid tumors. The key objectives are to explore a novel monomeric chimeric antigen receptor (CAR) design to optimize NK cell signaling and function, and to define a donor selection algorithm for CAR NK cell products. The award aims to leverage the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $3,182,665 to The Washington University to investigate how natural killer (NK) cells can subvert the effectiveness of immune checkpoint therapy for cancer treatment. The key objectives are to: 1) elucidate the mechanisms by which NK cells constrain the efficacy of immune checkpoint therapy, 2) evaluate the contribution of the NKG2D receptor in this process, and 3) translate the findings...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), awarded a $399,444 Project Grant to Cancure LLC (Canzx Biotherapeutics) on August 1, 2025. The funding will support a feasibility study of a novel agent that aims to stimulate NK (natural killer) and CD8 T cells for potential use in treating solid tumors. The study seeks to address challenges with persistence and sustained function of these cell-based therapies in the solid...
- This $177,180 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Fred Hutchinson Cancer Center in Seattle, Washington supports research to improve engineered TCR-T cell therapy for solid tumors. The key goals are to investigate whether engineered TCR-T cells form PD-1+TCF1+ stem-like progenitor exhausted T cell populations in tumor-draining lymph nodes, similar to endogenous tumor-specific T cells. This could impact the long-term persistence...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,847,485 Project Grant to The University of Texas MD Anderson Cancer Center to advance next-generation CAR-NK (chimeric antigen receptor-modified natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025 through August 31, 2029, will support the development and clinical testing of an engineered CAR-NK cell product expressing an anti-CD5 scFv, IL-15 for...
- The National Cancer Institute (NCI) awarded a $402,600 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The primary goals of this 5-year project are to develop these CAR T-cell therapies and investigate the mechanism by which U5 snRNP is...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
- The National Cancer Institute awarded a $162,486 Project Grant to Northwestern University to develop "tunable microenvironment-responsive CAR T cells using synthetic gene circuits to enhance potency and safety" for the treatment of ovarian cancer. This grant, funded through the Cancer Research Manpower (CFDA 93.398) program, aims to engineer CAR T cells that can specifically target and treat solid tumors, which have posed challenges for current CAR T cell therapies. The project...
HARNESSING NATURAL KILLER CELLS FOR CELLULAR IMMUNOTHERAPY AGAINST SOLID TUMORS - PROJECT SUMMARY/ABSTRACT DESPITE RECENT ADVANCES IN CANCER THERAPY, CANCER REMAINS THE SECOND LEADING CAUSE OF DEATH IN THE UNITED STATES. THE FIELD OF CANCER IMMUNOTHERAPY HAS EVOLVED TO MEET THIS CHALLENGE, BUT THERE IS AN ONGOING NEED FOR TREATING METASTATIC AND TREATMENT-RESISTANT SOLID TUMORS, PARTICULARLY THOSE OF LUNG, BREAST, PROSTATE, AND COLORECTAL ORIGIN. CELLULAR IMMUNOTHERAPIES, SUCH AS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, HAVE SHOWN SUCCESS IN TREATING BLOOD CANCERS. HOWEVER, THEY REMAIN INEFFECTIVE AGAINST SOLID TUMORS, AND ARE OFTEN FRAUGHT WITH INHERENT TOXICITIES SUCH AS CYTOKINE RELEASE SYNDROME AND ATTACK OF HEALTHY TISSUES. IN LIGHT OF THESE CHALLENGES, THIS PROPOSAL AIMS TO HARNESS NATURAL KILLER (NK) CELLS, WHICH HAVE BROAD ANTI-TUMOR ACTIVITY AND A SUPERIOR SAFETY PROFILE, TO GENERATE CAR NK-CELL THERAPY AS AN EFFECTIVE IMMUNOTHERAPY AGAINST SOLID TUMORS. CAR NK-CELL THERAPY HAS RECENTLY SHOWN REMARKABLE SUCCESS AGAINST BLOOD CANCERS BUT REMAINS CHALLENGING FOR USE IN SOLID TUMORS. THE TUMOR MICROENVIRONMENT EMPLOYS IMMUNE-EVASIVE MECHANISMS TO SUBVERT NK-CELL KILLING AND LIMITS THEIR INFILTRATION AND SURVIVAL. OUR RESEARCH PROPOSAL WILL ADDRESS THESE OBSTACLES BY LEVERAGING HIGH-THROUGHPUT, SEQUENCING-BASED FUNCTIONAL SCREENS AND INNOVATIVE SYNTHETIC BIOLOGY APPROACHES THAT WILL SHED LIGHT ON FUNDAMENTAL NK-CELL BIOLOGY AND ENHANCE CAR NK-CELL INFILTRATION AND KILLING OF SOLID TUMORS. WE WILL IMPLEMENT A GENOME-WIDE CRISPR SCREEN IN PRIMARY HUMAN NK CELLS TO IDENTIFY NEGATIVE REGULATORS ('INNATE IMMUNE CHECKPOINTS') OF NK-CELL CYTOTOXICITY. SUBSEQUENTLY, WE WILL IDENTIFY HOMING AND SURVIVAL SIGNALS IN TUMOR- INFILTRATING IMMUNE CELLS BY MINING SINGLE-CELL RNA-SEQUENCING DATABASES. WE WILL THEN INTRODUCE THESE GENES INTO NK CELLS TO ENHANCE THEIR INFILTRATION AND SURVIVAL IN IN-VITRO AND IN-VIVO MODELS OF THE TUMOR MICROENVIRONMENT. FINALLY, WE WILL PERFORM A HIGH-THROUGHPUT CARPOOL SCREEN TO SIMULTANEOUSLY ASSESS HUNDREDS OF NK CELL-TAILORED CARS DESIGNED WITH NATIVE NK CELL-RECEPTOR SIGNALING MACHINERY TO MAXIMIZE CAR NK-CELL FUNCTIONING. IN SUMMARY, THIS PROPOSED RESEARCH INTRODUCES SEVERAL INNOVATIVE APPROACHES TO STUDY FUNDAMENTAL NK-CELL BIOLOGY AND ENGINEER NK-CELL BASED IMMUNOTHERAPIES AGAINST SOLID TUMORS. OUR PROJECT IS POISED TO UNCOVER NEW TARGETS IN NK CELLS FOR 'INNATE IMMUNE CHECKPOINT BLOCKADE' AS WELL AS CREATE THE NEXT-GENERATION OF CAR NK- CELL THERAPY FOR TREATING METASTATIC AND TREATMENT-RESISTANT CANCERS. ULTIMATELY, WE WILL ESTABLISH A PIPELINE OF TECHNOLOGIES THAT CAN BE APPLIED TO MANY CANCER TYPES IN ORDER TO BROADEN THE SCOPE OF IMMUNOTHERAPIES AGAINST CANCER AND TRANSFORM PATIENT CARE TO MITIGATE THE DEVASTATING IMPACT OF THIS DISEASE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($1m) | 9/8/25 | ||
| Not listed | $1.5m | 8/4/25 |